S-Amlodipine: An Isomer with Difference—Time to Shift from Racemic Amlodipine
Calcium channel blockers are among the first-line drugs for treatment of hypertension (HTN). S-amlodipine (S-AM), an S-enantiomer of amlodipine, is available in India and in other countries like China, Korea, Russia, Ukraine, and Nepal. Being clinically researched for nearly two decades, we performe...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | International Journal of Hypertension |
| Online Access: | http://dx.doi.org/10.1155/2018/8681792 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554886068174848 |
|---|---|
| author | Jamshed Dalal J. C. Mohan S. S. Iyengar Jagdish Hiremath Immaneni Sathyamurthy Sandeep Bansal Dhiman Kahali Arup Dasbiswas |
| author_facet | Jamshed Dalal J. C. Mohan S. S. Iyengar Jagdish Hiremath Immaneni Sathyamurthy Sandeep Bansal Dhiman Kahali Arup Dasbiswas |
| author_sort | Jamshed Dalal |
| collection | DOAJ |
| description | Calcium channel blockers are among the first-line drugs for treatment of hypertension (HTN). S-amlodipine (S-AM), an S-enantiomer of amlodipine, is available in India and in other countries like China, Korea, Russia, Ukraine, and Nepal. Being clinically researched for nearly two decades, we performed in-depth review of S-AM. This review discusses clinical evidence from total 42 studies (26 randomized controlled trials, 14 observational studies, and 2 meta-analyses) corroborating over 7400 patients treated with S-AM. Efficacy and safety of S-AM in HTN in comparison to racemic amlodipine, used as monotherapy and in combination with other antihypertensives, efficacy in angina, and pleiotropic benefits with S-AM, are discussed in this review. |
| format | Article |
| id | doaj-art-0ad974a93a3344e3ad4587f40364bd85 |
| institution | Kabale University |
| issn | 2090-0384 2090-0392 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hypertension |
| spelling | doaj-art-0ad974a93a3344e3ad4587f40364bd852025-02-03T05:50:15ZengWileyInternational Journal of Hypertension2090-03842090-03922018-01-01201810.1155/2018/86817928681792S-Amlodipine: An Isomer with Difference—Time to Shift from Racemic AmlodipineJamshed Dalal0J. C. Mohan1S. S. Iyengar2Jagdish Hiremath3Immaneni Sathyamurthy4Sandeep Bansal5Dhiman Kahali6Arup Dasbiswas7Centre for Cardiac Sciences, Kokilaben Dhirubhai Ambani Hospital, Mumbai, IndiaFortis Hospital, Shalimar Bagh, New Delhi, IndiaManipal Hospital, Bangalore, IndiaRuby Hall Clinic, Pune, IndiaApollo Hospitals, Chennai, IndiaDepartment of Cardiology, VMMC & Safdarjung Hospital, New Delhi, IndiaB M Birla Heart Research Centre, Kolkata, IndiaNRS Medical College and Hospital, Kolkata, IndiaCalcium channel blockers are among the first-line drugs for treatment of hypertension (HTN). S-amlodipine (S-AM), an S-enantiomer of amlodipine, is available in India and in other countries like China, Korea, Russia, Ukraine, and Nepal. Being clinically researched for nearly two decades, we performed in-depth review of S-AM. This review discusses clinical evidence from total 42 studies (26 randomized controlled trials, 14 observational studies, and 2 meta-analyses) corroborating over 7400 patients treated with S-AM. Efficacy and safety of S-AM in HTN in comparison to racemic amlodipine, used as monotherapy and in combination with other antihypertensives, efficacy in angina, and pleiotropic benefits with S-AM, are discussed in this review.http://dx.doi.org/10.1155/2018/8681792 |
| spellingShingle | Jamshed Dalal J. C. Mohan S. S. Iyengar Jagdish Hiremath Immaneni Sathyamurthy Sandeep Bansal Dhiman Kahali Arup Dasbiswas S-Amlodipine: An Isomer with Difference—Time to Shift from Racemic Amlodipine International Journal of Hypertension |
| title | S-Amlodipine: An Isomer with Difference—Time to Shift from Racemic Amlodipine |
| title_full | S-Amlodipine: An Isomer with Difference—Time to Shift from Racemic Amlodipine |
| title_fullStr | S-Amlodipine: An Isomer with Difference—Time to Shift from Racemic Amlodipine |
| title_full_unstemmed | S-Amlodipine: An Isomer with Difference—Time to Shift from Racemic Amlodipine |
| title_short | S-Amlodipine: An Isomer with Difference—Time to Shift from Racemic Amlodipine |
| title_sort | s amlodipine an isomer with difference time to shift from racemic amlodipine |
| url | http://dx.doi.org/10.1155/2018/8681792 |
| work_keys_str_mv | AT jamsheddalal samlodipineanisomerwithdifferencetimetoshiftfromracemicamlodipine AT jcmohan samlodipineanisomerwithdifferencetimetoshiftfromracemicamlodipine AT ssiyengar samlodipineanisomerwithdifferencetimetoshiftfromracemicamlodipine AT jagdishhiremath samlodipineanisomerwithdifferencetimetoshiftfromracemicamlodipine AT immanenisathyamurthy samlodipineanisomerwithdifferencetimetoshiftfromracemicamlodipine AT sandeepbansal samlodipineanisomerwithdifferencetimetoshiftfromracemicamlodipine AT dhimankahali samlodipineanisomerwithdifferencetimetoshiftfromracemicamlodipine AT arupdasbiswas samlodipineanisomerwithdifferencetimetoshiftfromracemicamlodipine |